Last Updated: September 28, 2026

ALTACE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Altace, and what generic alternatives are available?

Altace is a drug marketed by King Pharms Llc and King Pfizer and is included in two NDAs.

The generic ingredient in ALTACE is ramipril. Seventeen suppliers are listed for this compound. Additional details are available on the ramipril profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Altace

A generic version of ALTACE was approved as ramipril by WATSON LABS on October 24th, 2005.

  Start Trial

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for ALTACE?
  • What are the global sales for ALTACE?
  • What is Average Wholesale Price for ALTACE?
Summary for ALTACE
US Patents:0
Applicants:2
NDAs:2

US Patents and Regulatory Information for ALTACE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
King Pharms Llc ALTACE ramipril CAPSULE;ORAL 019901-001 Jan 28, 1991 DISCN Yes No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
King Pfizer ALTACE ramipril TABLET;ORAL 022021-003 Feb 27, 2007 DISCN Yes No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
King Pharms Llc ALTACE ramipril CAPSULE;ORAL 019901-004 Jan 28, 1991 DISCN Yes No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
King Pfizer ALTACE ramipril TABLET;ORAL 022021-004 Feb 27, 2007 DISCN Yes No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
King Pharms Llc ALTACE ramipril CAPSULE;ORAL 019901-002 Jan 28, 1991 DISCN Yes No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
King Pharms Llc ALTACE ramipril CAPSULE;ORAL 019901-003 Jan 28, 1991 DISCN Yes No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for ALTACE

See the table below for patents covering ALTACE around the world.

Country Patent Number Title Estimated Expiration
Austria 20469 ⤷  Start Trial
Australia 4671885 ⤷  Start Trial
Australia 554362 ⤷  Start Trial
Australia 581919 ⤷  Start Trial
Australia 7661481 ⤷  Start Trial
Canada 1244041 PROCEDE DE PREPARATION DU CIS, ENDO-OCTAHYDROCYCLOPENTA [B]PYRROLE-2- CARBOXYLATE (PROCESS FOR THE PREPARATION OF CIS, ENDO- OCTAHYDROCYCLOPENTA[B]PYRROLE-2-CARBOXYLATE) ⤷  Start Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for ALTACE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0050800 96C0028 Belgium ⤷  Start Trial PRODUCT NAME: PORFIMERE SODIQUE; NAT. REGISTRATION NO/DATE: NL 19150 19960409; FIRST REGISTRATION: NL - RVG 16652 19940411
0265685 99C0001 Belgium ⤷  Start Trial PRODUCT NAME: FELODIPINUM + RAMIPRILUM; NATL. REGISTRATION NO/DATE: 354 IS 373 F 3 19981103; FIRST REGISTRATION: SE 13597 19970919
0265685 SPC/GB98/047 United Kingdom ⤷  Start Trial PRODUCT NAME: COMBINATIONS OF RAMIPRIL, OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF, AND FELODIPINE, OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF.; REGISTERED: SE 13596 19970919; SE 13597 19970919; UK 00017/0402 19980825; UK 00017/0403 19980825
0079022 SPC/GB93/145 United Kingdom ⤷  Start Trial SPC/GB93/145, EXPIRES: 20040109
0265685 C980030 Netherlands ⤷  Start Trial PRODUCT NAME: FELODIPINE, DESGEWENST IN DE VORM VAN FYSIOLOGISCH AANVAARDBAAR ZOUT, EN (2S, 3AS, 6AS)-1-[(S)-N-[(S)-1-CARBOXY-3-FENYLPROPYL]A LANYL]OCTAHYDROCYCLOPENTA[B]-PYRROOL-2-CARBONZUUR (RAMIPRILAAT) , DESGEWENST IN DE VORM VAN EEN .....ZIE VERDER IN HET DOSSIER; NAT. REGISTRATION NO/ DATE: RVG 22449, RVG 22450 19980618; FIRST REGISTRATION: SE 13596, 13597 19970919
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.